DBV Technologies (NASDAQ:DBVT) Stock Price Crosses Below Two Hundred Day Moving Average - Time to Sell?

Key Points

• DBV Technologies shares fell below the 200-day moving average of $17.94, trading as low as $13.40 before closing at $13.61 on volume of 185,679 shares.
• Analyst sentiment is mixed: some firms downgraded the stock to “sell,” while others maintain “buy” or “market outperform” ratings. Overall, the consensus remains “Moderate Buy” with an average price target of $48.50.
• Institutional investors and hedge funds own approximately 71.74% of DBVT. DBV Technologies is a clinical-stage biopharmaceutical company developing allergy immunotherapies, led by its Viaskin Peanut candidate.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $17.94 and traded as low as $13.40. DBV Technologies shares last traded at $13.61, with a volume of 185,679 shares trading hands.

Wall Street Analyst Weigh In

Several research firms have issued reports on DBVT. Weiss Ratings cut DBV Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, July 17th. HC Wainwright reaffirmed a "buy" rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Wall Street Zen cut DBV Technologies from a "hold" rating to a "sell" rating in a report on Saturday, July 4th. Finally, Citizens Jmp boosted their price objective on shares of DBV Technologies from $47.00 to $55.00 and gave the company a "market outperform" rating in a report on Tuesday, June 30th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $48.50.

DBV Technologies Stock Up 1.4%

The company has a market cap of $855.80 million, a PE ratio of -3.88 and a beta of -0.95. The business has a 50-day simple moving average of $14.68 and a 200-day simple moving average of $17.94.

Hedge Funds Weigh In On DBV Technologies

Several hedge funds have recently bought and sold shares of DBVT. Perceptive Advisors LLC purchased a new position in DBV Technologies during the 1st quarter valued at about $20,146,000. Vivo Capital LLC increased its stake in DBV Technologies by 8.4% during the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company's stock worth $55,726,000 after purchasing an additional 205,943 shares during the period. ADAR1 Capital Management LLC purchased a new stake in DBV Technologies during the first quarter worth about $21,159,000. Royal Bank of Canada increased its stake in DBV Technologies by 167.1% during the first quarter. Royal Bank of Canada now owns 4,680 shares of the company's stock worth $98,000 after purchasing an additional 2,928 shares during the period. Finally, Elmind Capital LP acquired a new stake in shares of DBV Technologies during the first quarter worth about $5,536,000. Institutional investors and hedge funds own 71.74% of the company's stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source